Association between the ABCG2 C421A polymorphism and Alzheimer's disease

[1]  Z. Janka,et al.  No association between CALHM1 polymorphism and Alzheimer's disease risk in a Hungarian population , 2011, Psychiatric genetics.

[2]  R. Faull,et al.  ABC efflux transporters in brain vasculature of Alzheimer's subjects , 2010, Brain Research.

[3]  L. Lue,et al.  ABCG2 Is Upregulated in Alzheimer's Brain with Cerebral Amyloid Angiopathy and May Act as a Gatekeeper at the Blood–Brain Barrier for Aβ1–40 Peptides , 2009, The Journal of Neuroscience.

[4]  T. Ishikawa,et al.  Major SNP (Q141K) Variant of Human ABC Transporter ABCG2 Undergoes Lysosomal and Proteasomal Degradations , 2009, Pharmaceutical Research.

[5]  Katie Hamm,et al.  apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. , 2008, The Journal of clinical investigation.

[6]  S. Steinberg,et al.  Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival , 2008, BJU international.

[7]  O. Wolkenhauer,et al.  Clinico-pathologic function of cerebral ABC transporters - implications for the pathogenesis of Alzheimer's disease. , 2008, Current Alzheimer research.

[8]  C. Johanson,et al.  Apolipoprotein E, Amyloid-&bgr;, and Blood-Brain Barrier Permeability in Alzheimer Disease , 2008, Journal of neuropathology and experimental neurology.

[9]  Jian-hua Chang,et al.  BCRP gene polymorphisms are associated with susceptibility and survival of diffuse large B-cell lymphoma. , 2007, Carcinogenesis.

[10]  K. Linton.  Structure and function of ABC transporters. , 2007, Physiology.

[11]  T. Molnár,et al.  P120 The Atp-Binding Cassette Transporter ABCG2 (BCRP) and ABCB1 (MDR1) Variants are not Associated With Disease Susceptibility, Disease Phenotype, Response to Medical Therapy or Need For Surgery in Hungarian Patients with Inflammatory Bowel Diseases , 2007 .

[12]  A. Tordai,et al.  ATP-binding cassette transporter ABCG2 (BCRP) and ABCB1 (MDR1) variants are not associated with disease susceptibility, disease phenotype response to medical therapy or need for surgeryin Hungarian patients with inflammatory bowel diseases , 2007, Scandinavian journal of gastroenterology.

[13]  Miles C. Miller,et al.  RAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease , 2006, Acta Neuropathologica.

[14]  R. Mahley,et al.  Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Y. Hinoda,et al.  Association of the BCRP C421A polymorphism with nonpapillary renal cell carcinoma , 2005, International journal of cancer.

[16]  A. Fagan,et al.  P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. , 2005, The Journal of clinical investigation.

[17]  Qingcheng Mao,et al.  Role of the breast cancer resistance protein (ABCG2) in drug transport , 2005, The AAPS Journal.

[18]  S. Bates,et al.  Single nucleotide polymorphisms modify the transporter activity of ABCG2 , 2005, Cancer Chemotherapy and Pharmacology.

[19]  Y. Sugiyama,et al.  Functional Analysis of SNPs Variants of BCRP/ABCG2 , 2004, Pharmaceutical Research.

[20]  H. McLeod,et al.  ABCG2 Pharmacogenetics , 2004, Clinical Cancer Research.

[21]  M. Nedergaard,et al.  The blood–brain barrier: an overview Structure, regulation, and clinical implications , 2004, Neurobiology of Disease.

[22]  B. Zlokovic.  Clearing amyloid through the blood–brain barrier , 2004, Journal of neurochemistry.

[23]  H. Kotani,et al.  Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2 , 2004, International journal of cancer.

[24]  Christiane Kunert-Keil,et al.  Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. , 2002, Pharmacogenetics.

[25]  Y. Miki,et al.  C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. , 2002, Molecular cancer therapeutics.

[26]  D. Holtzman,et al.  Plaque‐associated disruption of CSF and plasma amyloid‐β (Aβ) equilibrium in a mouse model of Alzheimer's disease , 2002, Journal of neurochemistry.

[27]  D. Selkoe.  Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[28]  Peter B. Reiner,et al.  β‐Amyloid efflux mediated by p‐glycoprotein , 2001 .

[29]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[30]  E. Schuetz,et al.  Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. , 2003, Pharmacogenetics.

[31]  E M Wijsman,et al.  The number of trait loci in late-onset Alzheimer disease. , 2000, American journal of human genetics.